Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has issued an announcement.
Botanix Pharmaceuticals has outlined details of its previously announced capital raising, including a two-tranche placement targeting A$40 million and an underwritten security purchase plan of up to A$5 million, offering eligible shareholders up to A$30,000 in new shares at A$0.06 each with 1:1 attaching options, all subject to shareholder approval at an extraordinary general meeting on 1 April 2026. The ASX has granted Botanix a waiver from Listing Rule 7.3.9 so that eligible shareholders can vote on the issue of securities under the SPP, removing a potential procedural hurdle and enabling broader shareholder participation in approving the equity raising, while still requiring voting exclusions for any underwriters and maintaining compliance with other listing rules.
The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals is a clinical dermatology company listed on the ASX that develops pharmaceutical treatments for skin conditions. The company focuses on capital-intensive clinical programs and uses equity raisings, including placements and security purchase plans, to fund its development pipeline and advance its products toward commercialisation.
Average Trading Volume: 8,313,114
Technical Sentiment Signal: Sell
Current Market Cap: A$124.2M
For an in-depth examination of BOT stock, go to TipRanks’ Overview page.